Clinical outcomes and sick leave in relation to UDCA treatment in Swedish patients with primary biliary cholangitis

References

• Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet. 2015;386(10003):1565–1575.
   PubMed Web of Science ®Google Scholar
• Lleo A, Wang GQ, Gershwin ME, et al. Primary biliary cholangitis. Lancet. 2020;396(10266):1915–1926.
   PubMed Web of Science ®Google Scholar
• Marschall HU, Henriksson I, Lindberg S, et al. Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide swedish population-based cohort. Sci Rep. 2019;9(1):11525.
   PubMedGoogle Scholar
• European Association for the Study of the Liver. Electronic address eee, european association for the study of the L. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–172.
   PubMed Web of Science ®Google Scholar
• Lleo A, Jepsen P, Morenghi E, et al. Evolving trends in female to male incidence and male mortality of primary biliary cholangitis. Sci Rep. 2016;6:25906.
   PubMed Web of Science ®Google Scholar
• Blackburn P, Freeston M, Baker CR, et al. The role of psychological factors in the fatigue of primary biliary cirrhosis. Liver Int. 2007;27(5):654–661.
   PubMed Web of Science ®Google Scholar
• Aberg F, Hockerstedt K, Roine RP, et al. Influence of liver-disease etiology on long-term quality of life and employment after liver transplantation. Clin Transplant. 2012;26(5):729–735.
   PubMed Web of Science ®Google Scholar
• Carbone M, Sharp SJ, Flack S, et al. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology. 2016;63(3):930–950.
   PubMed Web of Science ®Google Scholar
• Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48(3):871–877.
   PubMed Web of Science ®Google Scholar
• Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55(6):1361–1367.
   PubMed Web of Science ®Google Scholar
• Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136(4):1281–1287.
   PubMed Web of Science ®Google Scholar
• Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130(3):715–720.
   PubMed Web of Science ®Google Scholar
• Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105(10):2186–2194.
   PubMed Web of Science ®Google Scholar
• Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology. 2015;149(7):1804–1812 e4.
   PubMed Web of Science ®Google Scholar
• Harms MH, Lammers WJ, Thorburn D, et al. Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome. Am J Gastroenterol. 2018;113(2):254–264.
   PubMed Web of Science ®Google Scholar
• John BV, Khakoo NS, Schwartz KB, et al. Ursodeoxycholic acid response is associated with reduced mortality in primary biliary cholangitis with compensated cirrhosis. Am J Gastroenterol. 2021;116(9):1913–1923.
   PubMed Web of Science ®Google Scholar
• Ornolfsson KT, Lund SH, Olafsson S, et al. Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study. Scand J Gastroenterol. 2019;54(5):609–616.
   PubMed Web of Science ®Google Scholar
• Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology. 2013;144(3):560–569.e7. quiz e13-4.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases. Hepatology. 2019;69(1):394–419.
   PubMed Web of Science ®Google Scholar
• Royston P, Sauerbrei W. Building multivariable regression models with continuous covariates in clinical epidemiology–with an emphasis on fractional polynomials. Methods Inf Med. 2005;44(04):561–571.
   PubMed Web of Science ®Google Scholar
• Kubota J, Ikeda F, Terada R, et al. Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population. J Gastroenterol. 2009;44(9):1000–1006.
   PubMed Web of Science ®Google Scholar
• Tillmann HL, Wiese M, Braun Y, et al. Quality of life in patients with various liver diseases: patients with HCV show greater mental impairment, while patients with PBC have greater physical impairment. J Viral Hepat. 2011;18(4):252–261.
   PubMed Web of Science ®Google Scholar
• European Commission. Women´s employment in the EU 2020 [updated 2021 22 Sept cited 2020 March 06].
   Google Scholar
• Nordic Social Statistical Committee. Sickness Absence in the Nordic Countries Copenhagen; 2015. [cited 2021 Sept 22].
   Google Scholar
• Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014;147(6):1338–1349.e5. quiz e15.
   PubMed Web of Science ®Google Scholar